Aprogen Medicines Inc. announced a private placement of series 29 bearer-type non-guaranteed private convertible bonds for a gross proceeds of KRW 70,000,000,000 on September 8, 2023. The transaction has been approved by the board of directors of the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,383 KRW | +15.83% | +17.10% | +44.06% |
05-14 | Aprogen Medicines Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-19 | Aprogen Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+44.06% | 252M | |
+7.78% | 5.64B | |
-3.43% | 2.9B | |
-16.48% | 2.33B | |
-21.38% | 1.44B | |
-4.11% | 1.04B | |
-42.90% | 746M | |
-4.20% | 620M | |
-33.98% | 633M | |
+2.83% | 525M |
- Stock Market
- Equities
- A007460 Stock
- News Aprogen Medicines Inc.
- Aprogen Medicines Inc. announced that it expects to receive KRW 70 billion in funding